EUCTR2006-005689-38-HU进行中（未招募）不适用
EVALUATION OF THE EFFECT OF 4 WEEKS TREATMENT WITH CHF 4226 pMDI 2µg DOSE GIVEN ONCE DAILY IN THE EVENING ON 24-HOUR TROUGH FEV1 IN ADULT AND ADOLESCENT PATIENTS AGED 15 YEARS OR OVER WITH MODERATE OR SEVERE PERSISTANT ASTHMA.A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL GROUP, PLACEBO AND ACTIVE (FORMOTEROL 12µg B.I.D.) CONTROLLED, EFFICACY, SAFETY AND TOLERABILITY STUDY.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients will be enrolled at Visit 1 into the run-in period if they meet all the following criteria:
- •·Written informed consent obtained;
- •·Male or female patients aged 15 years and over;
- •·Moderate or severe persistent asthma according to the GINA 2005 Classification of Asthma Severity by Daily Medication Regimen and Response to Treatment”;
- •·Patients free of long-acting ß2 agonists treatment (LABAs) at least for 4 weeks before the screening visit and already treated for at least 1 month with inhaled corticosteroids at a stable dose corresponding to mild-medium asthma severity (GINA 2005) (up to 1000 µg BDP CFC or equivalent);
- •·Level of asthma control on existing therapy, defined as presence of day-time asthma symptoms > once a week and nocturnal asthma symptoms > twice a month. These findings are to be based on recent medical history and are to be confirmed at the end of the run-in period;
- •·Forced expiratory volume in the first second (FEV1) less or equal to 90% of predicted for the patient normal value and not less than 0.9 L in absolute value;
- •·Positive response to the reversibility test in the screening visit, defined as an increase of at least 12% and at least 250 mL from pre-dosing value in the measurement of FEV1 30 minutes following 2 puffs (2 x 100 µg) of inhaled salbutamol pMDI;
- •·Non-smokers or ex-smokers < 5 pack-year [e.g. less than 1 pack cigarettes (i.e. 20 cigarettes) per day for 5 years or 2 packs cigarettes per day for 2.5 years] and having stopped smoking > 1 year;
- •·A co-operative attitude and ability to be trained to correctly use the pMDI and the Aerolizer® inhaler;
- •·At the end of the run-in period, the presence of day-time asthma symptoms > once a week (but not every day) and nocturnal asthma symptoms > twice a month is to be confirmed by means of patient interview by the investigator.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will not be enrolled at Visit 1 into the run-in period if they meet any of the following criteria:
- •·Inability to carry out pulmonary function testing;
- •·Diagnosis of COPD as defined by the current GOLD guidelines;
- •·Current smoker or ex-smoker with total cumulative exposure equal or more than 5 pack-years and/or having stopped smoking one year or less prior to study start;
- •·History of near fatal asthma or of a past hospitalisation for asthma in an intensive care unit;
- •·History of significant seasonal variation of asthma;
- •·Evidence of severe asthma exacerbation or symptomatic infection of the airways in the previous 4 weeks (e.g. oral corticosteroids intake);
- •·Hospitalisation due to asthma during the previous 8 weeks;
- •·Patients treated with oral or intravenous corticosteroids in the past 4 weeks or depot injectable corticosteroids in the past 8 weeks;
- •·Patients treated with short-acting ß2-agonists in the past 8 hours, short-acting anticholinergics in the past 12 hours, long-acting anticholinergics (i.e. tiotropium bromide) in the past 48 hours, leukotriene modifiers in the past 2 weeks;
- •·Patients treated with oral or nebulized bronchodilators in the 4 weeks prior to study start;
- •·Patients treated with nebulized corticosteroids in the 4 weeks prior to study start;
- •·Patients who have changed their dose or formulation of inhaled or nasal corticosteroids during the previous 4 weeks;
- •·Patients treated with fixed combination of inhaled corticosteroids and ß2-agonists (e.g. Seretide®, Symbicort®) during the previous 4 weeks prior to study start;
- •·Patients undergoing immunotherapy;
- •·Patients treated with a xanthine derivative (e.g. theophylline) any formulation in the 4 weeks prior to study start;
- •·Patients treated with sodium cromoglycate or nedocromil sodium in the 4 weeks prior to study start;
- •·History or current evidence of heart failure, coronary artery disease, myocardial infarction, severe uncontrolled hypertension, cardiac arrhythmias or any other significant cardiac disease;
- •·Patients with a QTc interval (Bazett’s formula) in the ECG test > 450 msec in males or > 470 msec in females;
- •·Serum potassium < 3.5 mmol/L or > 6.0mmol/L;
- •·Clinically significant or unstable concurrent disease, e.g. uncontrolled diabetes mellitus; uncontrolled hyperthyroidism, significant hepatic impairment, significant pulmonary disease other than asthma (e.g. tuberculosis, lung cancer), gastrointestinal disease (e.g. active peptic ulcer), neurological or haematological autoimmune disorders;
- •·Cancer or any other chronic disease with poor prognosis and/or affecting patient status;
- •·Pregnant or lactating females or females at risk of pregnancy, i.e. those not making use of an effective contraceptive method (oral contraception, IUD, tubal ligature, double barrier method). A pregnancy test will be performed at screening in women of childbearing potential;
- •·History of alcohol or drug abuse;
- •·Patients treated with monoamine oxidase inhibitors, tricyclic antidepressants or beta-blockers;
- •·Allergy, sensitivity or intolerance to beta2-adrenergic agonists and/or study drug formulation ingredients;
- •·Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study;
- •·Patients who received any investigational new drug within the last 8 weeks.
研究者
相似试验
进行中（未招募）
1 期
EVALUATION OF THE EFFECT OF 4 WEEKS TREATMENT WITH CHF 4226 pMDI 2µg DOSE GIVEN ONCE DAILY IN THE EVENING ON 24-HOUR TROUGH FEV1 IN ADULT AND ADOLESCENT PATIENTS AGED 15 YEARS OR OVER WITH MODERATE OR SEVERE PERSISTANT ASTHMA. A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL GROUP, PLACEBO AND ACTIVE (FORMOTEROL 12µg B.I.D.) CONTROLLED, EFFICACY, SAFETY AND TOLERABILITY STUDY.Persistent asthmaMedDRA version: 14.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2006-005689-38-GBChiesi Farmaceutici S.p.A.240
进行中（未招募）
1 期
EVALUATION OF THE EFFECT OF 4 WEEKS TREATMENT WITH CHF 4226 pMDI 2µg DOSE GIVEN ONCE DAILY IN THE EVENING ON 24-HOUR TROUGH FEV1 IN ADULT AND ADOLESCENT PATIENTS AGED 15 YEARS OR OVER WITH MODERATE OR SEVERE PERSISTANT ASTHMA.A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL GROUP, PLACEBO AND ACTIVE (FORMOTEROL 12µg B.I.D.) CONTROLLED, EFFICACY, SAFETY AND TOLERABILITY STUDY.Persistent asthmaMedDRA version: 8.1Level: PTClassification code 10003553Term: AsthmaEUCTR2006-005689-38-BGChiesi Farmaceutici S.p.A.240
进行中（未招募）
1 期
Comparative study of the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on bone biomarkers in young women with low calcium intake. Prospective, monocenter, randomized, open-label, two-period,cross-over trialThe Active substance of Osteopor is Ossein Hydroxyapatite.Treatment of processes characterized by decalcification: osteoporosis, Cushing syndrome, thyrotoxicosis.MedDRA version: 9.1Level: LLTClassification code 10006956Term: Calcium deficiencyEUCTR2008-002280-14-FRPierre Fabre Médicament58
已完成
不适用
Efficacy and safety of a four-week treatment with budesonide/formoterol in patients with cough variant asthma: Open-label, randomized and parallel-group study compared with budesonide.Cough variant asthmaJPRN-UMIN000004383Kyoto University Graduate School of Medicine80
进行中（未招募）
不适用
ASSESSMENT OF EFFECTS OF A 12-MONTH TREATMENT WITH METFORMIN ON INSULIN ACTION AND SECRETION IN WOMEN WITH PRIOR GESTATIONAL DIABETES MELLITUS (GDM)previous gestational diabetes (GDM) and altered glucose metabolism in the post-partum period (Impaired Fasting Glucose or Impaired Gluocse Tolerance)MedDRA version: 14.1Level: PTClassification code 10018429Term: Glucose tolerance impairedSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2005-000899-40-ITGUIDOTTI